New drug CPV-104 enters first human trials for rare kidney disorder
Disease control
Recruiting now
This study tests a new medicine called CPV-104 for the first time in people. It is designed to calm an overactive part of the immune system that causes damage in C3 glomerulopathy (C3G), a rare kidney disease. The trial includes healthy adults and people with C3G to check safety,…
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Disease control
Last updated May 22, 2026 14:05 UTC